Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled time : 21:00 source : Www.curevac.com save search
[English only] CureVac Announces Voting Results of Extraordinary General Meeting
Published: 2023-03-28 (Crawled : 21:00) - curevac.com
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: 0.39%
H: 4.26%
C: 3.88%
meeting results
[English only] CureVac Announces Voting Results of General Meeting
Published: 2022-06-22 (Crawled : 21:00) - curevac.com
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: 0.49%
H: 4.45%
C: 3.82%
meeting results
CureVac besetzt die Stelle des Chief Development Officers neu – Myriam Mendila folgt auf Klaus Edvardsen
Published: 2022-06-08 (Crawled : 21:00) - curevac.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -0.05%
H: 0.0%
C: -2.17%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.9%
H: 0.52%
C: -1.74%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: -0.3%
H: 0.79%
C: -4.75%
CureVac beschleunigt Onkologie-Strategie mit Übernahme von Frame Cancer Therapeutics und fügt neuartige Antigen-Entdeckungsplattform hinzu
Published: 2022-06-08 (Crawled : 21:00) - curevac.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -0.05%
H: 0.0%
C: -2.17%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.9%
H: 0.52%
C: -1.74%
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: -0.3%
H: 0.79%
C: -4.75%
therapeutics cancer
CureVacs Daten der finalen Analyse der Phase 2b/3-Studie für CVnCoV, den Impfstoffkandidaten der ersten Generation, zeigen Schutzwirkung in Altersgruppe von 18 bis 60 Jahren
Published: 2021-06-30 (Crawled : 21:00) - curevac.com
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: -15.41%
H: 13.11%
C: 9.17%
phase 2 phase 2b cv2cov
[English only] CureVac Announces Voting Results of General Meeting
Published: 2021-06-24 (Crawled : 21:00) - curevac.com
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: 0.9%
H: 5.04%
C: 4.91%
results
CureVac gibt Status-Update zur Phase 2b/3-Studie für Impfstoffkandidat der ersten Generation CVnCoV bekannt
Published: 2021-06-16 (Crawled : 21:00) - curevac.com
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
|
| O: -46.63%
H: 16.31%
C: 14.31%
phase 2 phase 2b cv2cov
CureVacs Impfstoffkandidat der ersten Generation, CVnCoV, setzt nach DSMB-Empfehlung in Phase 2b/3 Wirksamkeitsnachweis in variantengeprägtem Umfeld fort
Published: 2021-05-28 (Crawled : 21:00) - curevac.com
CVAC | News | $2.44 -5.06% -5.33% 710K
|
Health Technology
| Email alert
Add to watchlist
phase 2 phase 2b cv2cov
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.